Publication | Closed Access

Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma

Hematological MalignancyMolecular PharmacologyOncologyMedicineMetronomic TherapyMultiple MyelomaPharmacotherapyAnti-cancer AgentInhibitor OmeprazolePharmacologyRadiation OncologyCancer ResearchCytochrome P450 2C19